Metraipolis › archive › dc_6335bd3484f2

Complete pathological response with pembrolizumab in recurrent sigmoid adenocarcinoma — Europe PMC PMID:41868703

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41868703
DOI
10.1093/jscr/rjag168
License (as archived)
solo-consultazione
Archived
2026-11-04T03:33:21.839Z
SHA-256 of the archived text
f4f53799138b2755359d9c22955d0038fb9bab50c3dcd2db9c069a9d7412f60f
Stable URL of this page
https://metraipolis.com/documento/dc_6335bd3484f2

How to cite

Complete pathological response with pembrolizumab in recurrent sigmoid adenocarcinoma — Europe PMC PMID:41868703 — Europe PMC (en), https://europepmc.org/article/MED/41868703 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6335bd3484f2 (Metraipolis archive dc_6335bd3484f2, sha256 f4f53799138b2755359d9c22955d0038fb9bab50c3dcd2db9c069a9d7412f60f)
BibTeX
@misc{dc6335bd3484f2,
  title = {Complete pathological response with pembrolizumab in recurrent sigmoid adenocarcinoma — Europe PMC PMID:41868703},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41868703},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6335bd3484f2; sha256 f4f53799138b2755359d9c22955d0038fb9bab50c3dcd2db9c069a9d7412f60f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41868703. Agents can read the archived copy with the MCP tool read_document.